Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
CD22 Molecule (CD22) antibody
|Synonyms||SIGLEC2, FLJ22814, SIGLEC-2, MGC130020|
Alternatives Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
|5 references available|
|Quantity||batch related (Variants)|
|Price||2,365.44 $ Plus shipping costs $45.00|
|Description||CD22 (Cluster of Differentiation 22) is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signalling CD22 antibodies are used in flow cytometry and immunohistochemistry as a pan B cell reagent, for the immunophenotyping of B cell lymphomas and HCL. It is more strongly expressed on prolymphocytic leukemia and HCL than in chronic lymphocytic leukemia. B cell lineage ALL, express membrane and cytoplasmic CD22. CD22 forms a loose complex with the BcR cell antigen receptor (BcR). The cytoplasmic domain is tyrosine phosphorylated upon ligation of the BCR and associates via SH2 domains with the tyrosine phosphatase SHP-1, the tyrosine kinase Syk and phospholipase C-g1. CD22 down-modulates the B cell activation threshold, presumably through its association with SHP-1 and other signaling molecules. Mice deficient in CD22 show exaggerated antibody responses to antigen and have raised levels of autoantibodies. CD22 can also mediate cell adhesion through its interaction with cell surface molecules bearing the appropriate sialoglycoconjugates,but only when these conjugates are not on the CD22 bearing cell itself. CD22 is detected in the cytoplasm early in B cell development (late pro-B cell stage), appears on the cell surface simultaneously with surface IgD, and is found on most mature B cells. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via surface Ig increases CD22 expression. CD22 reacts with most B cell leukemias including Hairy Cell Leukemia (HCL) and B cell lymphomas.|
|Specificity||Clone B-ly8, produces mouse IgG1 immunoglobulins directed against human CD22, molecular weight 130-140 kD.|
B-ly8 is a mouse monoclonal IgG1 antibody raised against CD22.
|Application Notes||Monoclonal antibody CD22, clone B-ly8 can be applied in flow cytometry for analysis of blood and bone marrow samples, or in immunohistochemistry using cytospots or frozen tissue sections. Optimal antibody dilution should be determined by titration.|
|Buffer||0.01 M sodium phosphate, 0.15 M NaCl, pH 7.3.|
|Storage||Store at 4°C.|
|Research Area||Stem Cells, Hematopoietic Progenitors, Adaptive Immunity, CD Antigens, Surface Receptors of Immune Cells|
|Restrictions||For Research Use only|
Schwartz-Albiez, Dörken, Monner et al.: "CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion." in: International immunology, Vol. 3, Issue 7, pp. 623-33, 1991 (PubMed).
Law, Sidorenko, Clark: "Regulation of lymphocyte activation by the cell-surface molecule CD22." in: Immunology today, Vol. 15, Issue 9, pp. 442-9, 1994 (PubMed).
Law, Sidorenko, Chandran et al.: "CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation." in: The Journal of experimental medicine, Vol. 183, Issue 2, pp. 547-60, 1996 (PubMed).
Doody, Dempsey, Fearon: "Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1." in: Current opinion in immunology, Vol. 8, Issue 3, pp. 378-82, 1997 (PubMed).
OKeefe, Williams, Davies et al.: "Hyperresponsive B cells in CD22-deficient mice." in: Science (New York, N.Y.), Vol. 274, Issue 5288, pp. 798-801, 1996 (PubMed).